InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Preclinical Results for Age-Related Macular Degeneration
Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced reactive oxygen species (ROS) induced by copper and iron exposure in human retinal cell lines. The findings suggest Telomir-1’s potential as a disease-modifying therapy for age-related macular degeneration (AMD) by targeting oxidative stress, a key driver of retinal degeneration. The company plans further in vivo studies to evaluate Telomir-1’s efficacy…